Estradiol improves genital herpes vaccine efficacy in mice

Jeffry W. Pennock, Rachael Stegall, Brent Bell, Gracie Vargas, Massoud Motamedi, Gregg Milligan, Nigel Bourne

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Herpes Simplex Virus type 2 causes genital herpes but is frequently transmitted asymptomatically; therefore, a prophylactic vaccine is desirable. A candidate vaccine in clinical trials has only shown efficacy in preventing disease in women. Using this subunit vaccine candidate, we were able to demonstrate infection prophylaxis, improved disease prevention and modulated antibody production by complimenting vaccination with estradiol in our murine model. Findings of estradiol-enhanced vaccine efficacy are the first of their kind using a vaccine of this type and have potential clinical relevance to the development of other vaccines and our understanding of gender differences in vaccine efficacy.

Original languageEnglish (US)
Pages (from-to)5830-5836
Number of pages7
JournalVaccine
Volume27
Issue number42
DOIs
StatePublished - Sep 25 2009

Fingerprint

Herpes Genitalis
genitalia
estradiol
Estradiol
Vaccines
vaccines
mice
Human herpesvirus 2
subunit vaccines
disease prevention
vaccine development
antibody formation
Subunit Vaccines
Human Herpesvirus 2
gender differences
clinical trials
disease control
animal models
Antibody Formation
vaccination

Keywords

  • Estradiol
  • Herpes Simplex Virus Vaccines
  • Herpesvirus 2
  • Human

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Estradiol improves genital herpes vaccine efficacy in mice. / Pennock, Jeffry W.; Stegall, Rachael; Bell, Brent; Vargas, Gracie; Motamedi, Massoud; Milligan, Gregg; Bourne, Nigel.

In: Vaccine, Vol. 27, No. 42, 25.09.2009, p. 5830-5836.

Research output: Contribution to journalArticle

Pennock, Jeffry W. ; Stegall, Rachael ; Bell, Brent ; Vargas, Gracie ; Motamedi, Massoud ; Milligan, Gregg ; Bourne, Nigel. / Estradiol improves genital herpes vaccine efficacy in mice. In: Vaccine. 2009 ; Vol. 27, No. 42. pp. 5830-5836.
@article{dd47788275964f87817c1fe5bbb539b0,
title = "Estradiol improves genital herpes vaccine efficacy in mice",
abstract = "Herpes Simplex Virus type 2 causes genital herpes but is frequently transmitted asymptomatically; therefore, a prophylactic vaccine is desirable. A candidate vaccine in clinical trials has only shown efficacy in preventing disease in women. Using this subunit vaccine candidate, we were able to demonstrate infection prophylaxis, improved disease prevention and modulated antibody production by complimenting vaccination with estradiol in our murine model. Findings of estradiol-enhanced vaccine efficacy are the first of their kind using a vaccine of this type and have potential clinical relevance to the development of other vaccines and our understanding of gender differences in vaccine efficacy.",
keywords = "Estradiol, Herpes Simplex Virus Vaccines, Herpesvirus 2, Human",
author = "Pennock, {Jeffry W.} and Rachael Stegall and Brent Bell and Gracie Vargas and Massoud Motamedi and Gregg Milligan and Nigel Bourne",
year = "2009",
month = "9",
day = "25",
doi = "10.1016/j.vaccine.2009.07.052",
language = "English (US)",
volume = "27",
pages = "5830--5836",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "42",

}

TY - JOUR

T1 - Estradiol improves genital herpes vaccine efficacy in mice

AU - Pennock, Jeffry W.

AU - Stegall, Rachael

AU - Bell, Brent

AU - Vargas, Gracie

AU - Motamedi, Massoud

AU - Milligan, Gregg

AU - Bourne, Nigel

PY - 2009/9/25

Y1 - 2009/9/25

N2 - Herpes Simplex Virus type 2 causes genital herpes but is frequently transmitted asymptomatically; therefore, a prophylactic vaccine is desirable. A candidate vaccine in clinical trials has only shown efficacy in preventing disease in women. Using this subunit vaccine candidate, we were able to demonstrate infection prophylaxis, improved disease prevention and modulated antibody production by complimenting vaccination with estradiol in our murine model. Findings of estradiol-enhanced vaccine efficacy are the first of their kind using a vaccine of this type and have potential clinical relevance to the development of other vaccines and our understanding of gender differences in vaccine efficacy.

AB - Herpes Simplex Virus type 2 causes genital herpes but is frequently transmitted asymptomatically; therefore, a prophylactic vaccine is desirable. A candidate vaccine in clinical trials has only shown efficacy in preventing disease in women. Using this subunit vaccine candidate, we were able to demonstrate infection prophylaxis, improved disease prevention and modulated antibody production by complimenting vaccination with estradiol in our murine model. Findings of estradiol-enhanced vaccine efficacy are the first of their kind using a vaccine of this type and have potential clinical relevance to the development of other vaccines and our understanding of gender differences in vaccine efficacy.

KW - Estradiol

KW - Herpes Simplex Virus Vaccines

KW - Herpesvirus 2

KW - Human

UR - http://www.scopus.com/inward/record.url?scp=69749118434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69749118434&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.07.052

DO - 10.1016/j.vaccine.2009.07.052

M3 - Article

VL - 27

SP - 5830

EP - 5836

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 42

ER -